Cell-specific MicroRNA networks orchestrate the pathogenesis of Alzheimer’s disease

May combine two claims.

NSC niches show reduced proliferation and impaired neuronal differentiation, ependymal ciliary activity becomes disrupted, and endothelial dysfunction contributes to BBB breakdown, vascular leakage, and neuroimmune dysregulation.

“NSC niches show reduced proliferation and impaired neuronal differentiation, ependymal ciliary activity becomes disrupted, and endothelial dysfunction contributes to BBB breakdown, vascular leakage, and neuroimmune dysregulation (Fu et al., 2019; Makibatake et al., 2023; Montagne et al., 2017; Sweeney et al., 2018).”

• cites Fu et al., 2019Not matched

  Couldn’t be matched to a paper in Crossref, so it can’t be checked.

• cites Makibatake et al., 2023 sourceSupported
• cites Montagne et al., 2017 sourcePartly supported

  The 'BBB breakdown in AD' section reports endothelial degeneration, capillary leakage, and immune-cell entry into the brain; the Figure 1 caption also links BBB breakdown to an inflammatory response. The paper does not address reduced proliferation or neuronal differentiation in NSC niches, or disrupted ependymal ciliary activity, so it supports only the vascular portion of the cited sentence. No page numbers are available in our copy. (LLM, conf=0.88)

  Experimental — accuracy not yet measured

May combine two claims.

Dysregulation of miRNAs is an important driver of AD progression, directly and indirectly influencing amyloidogenesis, tau hyperphosphorylation, and neuroinflammation.

“Dysregulation of these miRNAs is now recognized as an important driver of AD progression, directly and indirectly influencing core pathogenic mechanisms such as amyloidogenesis, tau hyperphosphorylation, and neuroinflammation (Hébert et al., 2008; Salta et al., 2016).”

• cites Hébert et al., 2008 sourcePartly supported

  The Abstract reports that reduced miR-29a/b-1 may increase BACE1 and Aβ levels, supporting a link to amyloidogenesis. The Discussion says whether altered miRNA expression is a cause or consequence of AD remains unresolved. Neither section supports the attributed effects on tau hyperphosphorylation or neuroinflammation. (LLM, conf=0.90)

  Experimental — accuracy not yet measured
• cites Salta et al., 2016 sourcePartly supported

  The Results (page not available in our copy) show that loss of miR-132 aggravates amyloid and TAU pathology in an AD mouse model, with corresponding changes observed in human AD brain. The Introduction says miR-132 has been implicated in neuroinflammation, but this paper does not establish an effect on neuroinflammation or show that dysregulated miRNAs broadly drive all three mechanisms. (LLM, conf=0.88)

  Experimental — accuracy not yet measured

May combine two claims.

Inhibiting miR-21-5p reduces gliosis and protects neuronal integrity.

“Inhibiting miR-21-5p reduces gliosis and protects neuronal integrity, making it a prime candidate for astrocyte-based therapeutic strategies (Banzhaf-Strathmann et al., 2014; Garcia et al., 2022; Wang et al., 2008).”

• cites Banzhaf-Strathmann et al., 2014 sourceNot checked — no full text of the source
• cites Garcia et al., 2022 sourceCould not verify

  The Discussion (section 4) links elevated miR-21 to astrocyte reactivity and neuronal dysfunction but says its protective or harmful role remains to be determined. The Conclusions (section 5) propose future tests of miR-21 inhibitors; they do not report that inhibition reduces gliosis or protects neurons. (LLM, conf=0.77)

  Experimental — accuracy not yet measured
• cites Wang et al., 2008Not matched

  Couldn’t be matched to a paper in Crossref, so it can’t be checked.

May combine two claims.

MiR-146a is elevated in reactive astrocytes in AD and is generally considered a compensatory anti-inflammatory regulator.

“MiR-146a is also elevated in reactive astrocytes in AD and is generally considered a compensatory anti-inflammatory regulator.”

• cites Fan et al., 2020 sourcePartly supported

  The Alzheimer’s Disease section reports increased miR-146a in the neocortex and hippocampus of patients with AD, but does not establish that the increase occurs specifically in reactive astrocytes. It calls miR-146a’s role in AD-related neuroinflammation controversial, while the Discussion and Perspective section proposes a compensatory inflammatory-suppressor role as a hypothesis needing further evidence. Page numbers are unavailable in our copy. (LLM, conf=0.87)

  Experimental — accuracy not yet measured
• cites Saba et al., 2012 sourcePartly supported

  The Discussion describes miR-146a as a possible inhibitory feedback regulator of inflammation, and the Results report reduced inflammatory cytokine production when it is overexpressed in stimulated microglia. The paper does not establish that miR-146a is elevated in reactive astrocytes in Alzheimer’s disease; its cell-line profiling instead places miR-146a in a microglia-enriched cluster. Page numbers were not available in our copy. (LLM, conf=0.87)

  Experimental — accuracy not yet measured
• cites Saba et al., 2014 sourcePartly supported

  The section “An Emerging Role for miR-146a in Neurodegenerative Disorders” reports elevated miR-146a in the brains and cerebrospinal fluid of patients with Alzheimer’s disease, but does not identify reactive astrocytes as the cells with elevated expression. It describes a possible protective, anti-inflammatory role in microglia, while emphasizing that this role is still emerging, rather than established in astrocytes. (LLM, conf=0.87)

  Experimental — accuracy not yet measured

May combine two claims.

In AD, intercellular networks become maladaptive, leading to sustained inflammation, impaired synaptic support, defective myelination, and breakdown of the blood-brain barrier, ultimately amplifying neurodegeneration.

“In AD, these networks become maladaptive, leading to sustained inflammation, impaired synaptic support, defective myelination (Nasrabady et al.; 2018, Zhou et al., 2022), and breakdown of the blood-brain barrier (BBB), ultimately amplifying neurodegeneration (Heneka et al., 2015; Sweeney et al., 2018).”

• cites Nasrabady et al., 2018 sourceSupported
• cites Zhou et al., 2022 sourceNot checked yet

  Checked before — its earlier verdict is held back until a new check runs.

• cites Heneka et al., 2015 sourcePartly supported

  The sections on microglia and the neurovascular unit describe persistent inflammation, impaired synaptic maintenance, vascular alterations, and processes that amplify neurodegeneration in AD. The neurovascular-unit passage discusses Aβ transport across the blood-brain barrier, but does not establish BBB breakdown. Defective myelination has separate citations in the sentence and is not assessed against Heneka et al. (LLM, conf=0.84)

  Experimental — accuracy not yet measured

May combine two claims.

Astrocytes become reactive and inflammatory, while microglia transition into chronically activated states that can amplify neuroinflammation.

“Astrocytes become reactive and inflammatory, while microglia transition into chronically activated states that can amplify neuroinflammation (Heneka et al., 2015; Sofroniew and Vinters, 2010).”

• cites Heneka et al., 2015 sourceSupported
• cites Sofroniew and Vinters, 2010 sourcePartly supported

  The section on reactive astrogliosis and CNS inflammation says reactive astrocytes can have pro-inflammatory effects, but also emphasizes their context-dependent anti-inflammatory effects. The cited paper does not establish that microglia transition into chronically activated states that amplify neuroinflammation; its discussion of chronic inflammation concerns signaling involving reactive astrocytes. (LLM, conf=0.88)

  Experimental — accuracy not yet measured

May combine two claims.

MiR-33 represses ABCA1, reducing cholesterol efflux and impairing ApoE lipidation, a process essential for microglial Aβ uptake and plaque compaction.

“MiR-33 plays a crucial role in microglial lipid biology. It represses ABCA1, reducing cholesterol efflux and impairing ApoE lipidation, a process essential for microglial Aβ uptake and plaque compaction (Tate et al., 2024).”

• cites Tate et al., 2024 sourcePartly supported

  The Background says ABCA1 mediates cholesterol efflux onto apoE, and the Results report increased ABCA1 and microglial Aβ uptake when miR-33 is inhibited. But the Discussion says apoE lipidation is mainly astrocyte-mediated and does not establish that it is essential for microglial Aβ uptake; the paper reports plaque deposition, not plaque compaction. Page numbers are unavailable in our copy. (LLM, conf=0.88)

  Experimental — accuracy not yet measured

May combine two claims.

AD is consistently associated with white-matter abnormalities and demyelination, contributing to cognitive and structural decline.

“The disease is consistently associated with white-matter abnormalities and demyelination, contributing to cognitive and structural decline (Nasrabady et al., 2018; Zhou et al., 2022; Zovoilis et al., 2011).”

• cites Nasrabady et al., 2018 sourceSupported
• cites Zhou et al., 2022 sourceNot checked yet

  Checked before — its earlier verdict is held back until a new check runs.

• cites Zovoilis et al., 2011 sourceNot checked yet

  Checked before — its earlier verdict is held back until a new check runs.

May combine two claims.

Through repression of TREM2 and SIRT1, miR-34a lowers microglial capacity to clear Aβ and promotes a sustained inflammatory phenotype, contributing to synaptic and metabolic decline.

“Through this repression, miR-34a lowers microglial capacity to clear Aβ and promotes a sustained inflammatory phenotype, contributing to synaptic and metabolic decline (Sarkar et al., 2016; Sarkar et al., 2019).”

• cites Sarkar et al., 2016 sourcePartly supported

  The Discussion (page not provided) proposes that miR-34a suppresses SIRT1 and could increase Aβ production; it does not say this reduces microglial clearance of Aβ. The Results, §2.2 (page not provided), link miR-34a overexpression to repression of synaptic and energy-metabolism proteins. Our copy does not support the attributed TREM2 repression or sustained microglial inflammatory phenotype. (LLM, conf=0.87)

  Experimental — accuracy not yet measured
• cites Sarkar et al., 2019 sourcePartly supported

  The Results report reduced SIRT1 protein in miR-34a-overexpressing mice, and the Discussion links SIRT1 inhibition to disrupted energy metabolism and inflammatory responses, alongside impaired synaptic function. But the cited paper does not establish TREM2 repression, reduced microglial Aβ clearance, or a sustained microglial inflammatory phenotype; its reported Aβ findings concern APP processing and predominantly intracellular Aβ. (LLM, conf=0.88)

  Experimental — accuracy not yet measured

May combine two claims.

OLs and OPCs are vulnerable to Aβ toxicity, oxidative stress, and inflammation, leading to impaired myelination and OL death.

“OLs and their precursor cells (OPCs) are vulnerable to Aβ toxicity, oxidative stress, and inflammation, leading to impaired myelination and OL death (Nasrabady et al., 2018; Wei et al., 2020; Zhou et al., 2022).”

• cites Nasrabady et al., 2018 sourcePartly supported

  In “Abnormalities of oligodendrocyte lineage cells in AD” (page unavailable), the review reports Aβ-induced oligodendrocyte death and dysfunction, and says oxidative stress impairs OPC differentiation. It does not establish that OPCs are vulnerable to Aβ toxicity or that inflammation causes oligodendrocyte or OPC injury; its mention of inflammation concerns white-matter hyperintensities, not those cells. (LLM, conf=0.86)

  Experimental — accuracy not yet measured
• cites Wei et al., 2020 sourceNot checked yet

  Checked before — its earlier verdict is held back until a new check runs.

• cites Zhou et al., 2022 sourceNot checked yet

  Checked before — its earlier verdict is held back until a new check runs.

May combine two claims.

Aβ exposure directly slows ependymal ciliary beating, impairs ventricular fluid flow, and exacerbates neurotoxicity in explant cultures.

“A recent study showed that Aβ exposure directly slows ependymal ciliary beating, impairs ventricular fluid flow, and exacerbates neurotoxicity in explant cultures (Makibatake et al., 2023).”

• cites Makibatake et al., 2023 sourcePartly supported

  The Discussion (page unavailable) reports that Aβ1–42 reduced peak ependymal ciliary beating in rat brain explants and decreased cilia-driven fluid flow. It describes enhanced neurotoxicity from that reduced flow as a possibility, not a demonstrated effect. The measured flow was culture-medium flow, rather than ventricular fluid flow in vivo. (LLM, conf=0.86)

  Experimental — accuracy not yet measured

May combine two claims.

Neuron-derived EV miR-132-3p decreases in CSF fractions and correlates with synaptic degeneration and cognitive decline.

“Neuron-derived EV miR-132-3p decreases in CSF fractions and correlates with synaptic degeneration and cognitive decline (Salta et al., 2016; Walgrave et al., 2021a).”

• cites Salta et al., 2016 sourcePartly supported

  The Results section on human AD brain reports that miR-132 was approximately twofold lower in prefrontal cortex samples than in non-demented controls (page not provided). It does not report measurements of neuron-derived extracellular vesicles or CSF fractions, or a correlation with synaptic degeneration or cognitive decline. (LLM, conf=0.86)

  Experimental — accuracy not yet measured
• cites Walgrave et al., 2021aNot matched

  Couldn’t be matched to a paper in Crossref, so it can’t be checked.

May combine two claims.

The distinct cell-type and stage-specific miRNA signatures in AD likely reflect a combination of cell-type-restricted transcription factor networks, differences in pri-miRNA processing/Dicer/Argonaute loading, subcellular localization of miRNAs, and selective EV packaging/uptake varying by donor and recipient cell type.

“This likely reflects a combination of factors: (i) cell-type–restricted transcription factor networks that regulate primary miRNA transcription; (ii) differences in primary microRNA (pri-miRNA) processing, Dicer activity, and Argonaute loading; (iii) subcellular localization of miRNAs to synapses, myelin, or perivascular end-feet; and (iv) selective packaging and uptake of miRNAs into EVs”

• cites Fan et al., 2020 sourcePartly supported

  The Alzheimer’s Disease subsection (page not provided) reports that miR-146a levels differ by tissue and Braak stage, supporting the stage-dependent part of the claim. It does not explain those differences through cell-type-restricted transcription, miRNA processing or loading, subcellular localization, or selective EV packaging and uptake; nor does it establish cell-type-specific miRNA signatures in AD. (LLM, conf=0.83)

  Experimental — accuracy not yet measured
• cites Kumar et al., 2022 sourcePartly supported

  The Results section, “Validation analysis of synaptosomal miRNAs” (page unavailable), reports miRNA differences across Braak stages and between synaptosomal and cytosolic fractions. It also finds Ago2, Drosha, and Dicer in those fractions, but does not establish differences in their activity or loading as causes of the signatures. The cited paper does not support the proposed cell-type-specific transcription networks, localization to myelin or perivascular end-feet, or selective EV packaging and uptake by donor and recipient cell types. (LLM, conf=0.88)

  Experimental — accuracy not yet measured
• cites Men et al., 2019 sourcePartly supported

  The Results section, “Identification of miR cargos in neuronal exosomes” (page unavailable), reports selective enrichment of miRNAs in neuronal exosomes, and “Elevated astroglial miR-124-3p involves neuronal exosomes” shows transfer to astrocytes. The paper does not establish that AD-specific or stage-specific signatures arise from transcription-factor networks, differences in pri-miRNA processing, Dicer activity or Argonaute loading, or localization to the listed subcellular sites. It says the mechanisms of miRNA sorting and exosome internalization are not well understood. (LLM, conf=0.88)

  Experimental — accuracy not yet measured

• AssumptionRests on an assumption: Neurons, astrocytes, microglia, oligodendrocytes, NSCs, and endothelial cells share many core genes but have distinct miRNA signatures with strong cell-type and stage specificity.

Classified as probably not a substantial claim.

miRNAs may complement existing diagnostic and therapeutic approaches by reflecting cell-type-specific and intercellular molecular alterations.

“MiRNAs may complement existing diagnostic and therapeutic approaches by reflecting cell-type-specific and intercellular molecular alterations.”

May combine two claims.

MiR-34a/c promotes apoptosis and impairs synaptic plasticity; their inhibition rescues memory in AD mouse models.

“MiR-34a/c also promotes apoptosis and impair synaptic plasticity; their inhibition rescues memory in AD mouse models (Banzhaf-Strathmann et al., 2014; Sarkar et al., 2016; Zovoilis et al., 2011).”

• cites Banzhaf-Strathmann et al., 2014 sourceNot checked — no full text of the source
• cites Sarkar et al., 2016 sourceNot checked yet

  Checked before — its earlier verdict is held back until a new check runs.

• cites Zovoilis et al., 2011 sourceNot checked yet

  Checked before — its earlier verdict is held back until a new check runs.

May combine two claims.

miR-188-5p maintains dendritic spine density by repressing Nrp2; its reduction under Aβ stress accelerates spine loss, while restoring miR-188-5p rescues synaptic and cognitive function in 5xFAD mice.

“miR-188-5p maintains dendritic spine density by repressing Nrp2; its reduction under Aβ stress accelerates spine loss, while restoring miR-188-5p rescues synaptic and cognitive function in 5xFAD mice (Lee et al., 2016).”

• cites Lee et al., 2016Not matched

  Couldn’t be matched to a paper in Crossref, so it can’t be checked.

May combine two claims.

MiR-125b is highly elevated and pathogenic in the AD brain, promoting tau hyperphosphorylation and apoptotic signaling by suppressing phosphatases such as DUSP6 and PPP1CA.

“MiR-125b is highly elevated and pathogenic in the AD brain, promoting tau hyperphosphorylation and apoptotic signaling by suppressing phosphatases such as DUSP6 and PPP1CA (Banzhaf-Strathmann et al., 2014).”

• cites Banzhaf-Strathmann et al., 2014 sourceNot checked — no full text of the source

May combine two claims.

MicroRNAs (miRNAs) have emerged as key modulators of cell-specific processes and are consistently dysregulated in AD.

“MicroRNAs (miRNAs), the small non-coding RNAs that regulate post-transcriptional gene expression, have emerged as key modulators of these cell-specific processes and are consistently dysregulated in AD.”

May combine two claims.

miR-132-3p is one of the most consistently reduced miRNAs in human AD hippocampus and cortex, represses ITPKB and other stress-responsive pathways that enhance tau phosphorylation, and restoring this miRNA rescues synaptic plasticity, dendritic complexity, and adult neurogenesis.

“miR-132-3p, one of the most consistently reduced miRNAs in human AD hippocampus and cortex, represses ITPKB and other stress-responsive pathways that enhance tau phosphorylation, and restoring this miRNA rescues synaptic plasticity, dendritic complexity, and adult neurogenesis (Salta et al., 2016; Walgrave et al., 2021a).”

• cites Salta et al., 2016 sourceNot checked yet

  Not checked in the free run.

• cites Walgrave et al., 2021aNot matched

  Couldn’t be matched to a paper in Crossref, so it can’t be checked.

May combine two claims.

Let-7b, enriched in CSF of AD patients, activates neuronal TLR7 and triggers neurotoxic inflammation.

“Let-7b, enriched in CSF of AD patients, activates neuronal TLR7 and triggers neurotoxic inflammation (Lehmann et al., 2012).”

• cites Lehmann et al., 2012 sourceNot checked — no full text of the source

May combine two claims.

In APP/PS1 mice, hippocampal overexpression of miR-124-3p lowers Aβ deposition, normalizes autophagy and calpain signaling, increases synaptic protein expression, and rescues learning and memory performance.

“In APP/PS1 mice, hippocampal overexpression of miR-124-3p via lentiviral or AAV delivery lowers Aβ deposition, normalizes autophagy and calpain signaling, increases synaptic protein expression, and rescues learning and memory performance (Du et al., 2017; Zhou et al., 2018).”

• cites Du et al., 2017Not matched

  Couldn’t be matched to a paper in Crossref, so it can’t be checked.

• cites Zhou et al., 2018 sourceNot checked — no full text of the source

May combine two claims.

In a recent study, miR-375-3p, in combination with rapamycin, modulated the mTOR pathway by decreasing PS1 expression, enhanced autophagic clearance, and improved microglial and neuronal resilience under AD-like stress.

“In a recent study, miR-375-3p, in combination with rapamycin, modulated the mTOR pathway by decreasing PS1 expression, enhanced autophagic clearance, and improved microglial and neuronal resilience under AD-like stress (Wang et al., 2024).”

• cites Wang et al., 2024Not matched

  Couldn’t be matched to a paper in Crossref, so it can’t be checked.

May combine two claims.

Neuron-derived EVs enriched in miR-132-3p or miR-124-3p can reprogram glial states, while glial EV cargo such as miR-155, miR-21-5p, and miR-146a feeds back onto neurons and other glia to propagate inflammatory or compensatory signals.

“For example, neuron-derived EVs enriched in miR-132-3p or miR-124-3p can reprogram glial states, while glial EV cargo such as miR-155, miR-21-5p, and miR-146a feeds back onto neurons and other glia to propagate inflammatory or compensatory signals (Aloi et al., 2023; Cardoso et al., 2011; Fan et al., 2020; Gaudet et al., 2017; Guedes et al., 2014; Han et al., 2020; Lukiw et al., 2008; Saba et al.,”

• cites Aloi et al., 2023Not matched

  Couldn’t be matched to a paper in Crossref, so it can’t be checked.

• cites Cardoso et al., 2011 sourceNot checked — no full text of the source
• cites Fan et al., 2020 sourceNot checked yet

  Checked before — its earlier verdict is held back until a new check runs.

May combine two claims.

miR-21-5p is one of the most strongly upregulated astrocytic miRNAs in AD; its levels are elevated in peri-plaque astrocytes, CSF, and plasma, where it suppresses PPARα, removing an anti-inflammatory checkpoint and promoting sustained NF-κB-mediated cytokine signaling.

“miR-21-5p is one of the most strongly upregulated astrocytic miRNAs in AD. Its levels are elevated in peri-plaque astrocytes, CSF, and plasma, where miR-21-5p suppresses PPARα, removing a critical anti-inflammatory checkpoint and promoting sustained NF-κB-mediated cytokine signaling (Garcia et al., 2022).”

• cites Garcia et al., 2022 sourceNot checked yet

  Not checked in the free run.

May combine two claims.

miR-124-3p is consistently reduced in AD models, and restoring its expression improves neuronal survival and synaptic integrity.

“In AD models, miR-124-3p is consistently reduced, and restoring its expression improves neuronal survival and synaptic integrity (Han et al., 2020).”

• cites Han et al., 2020 sourceNot checked yet

  Not checked in the free run.

May combine two claims.

Across AD-vulnerable brain regions and CNS cell types, miRNAs influence amyloid and tau biology, synaptic resilience, glial activation states, myelin structure, neurogenic potential, and vascular homeostasis.

“Across AD-vulnerable brain regions and CNS cell types, miRNAs influence amyloid and tau biology, synaptic resilience, glial activation states, myelin structure, neurogenic potential, and vascular homeostasis.”

May combine two claims.

MiR-107 represses BACE1 and shows early reduction in human temporal cortex, suggesting that its decline may contribute to preclinical disease progression.

“MiR-107, which also represses BACE1, shows early reduction in human temporal cortex, suggesting that its decline may contribute to preclinical disease progression (Wang et al., 2008).”

• cites Wang et al., 2008Not matched

  Couldn’t be matched to a paper in Crossref, so it can’t be checked.

May combine two claims.

Neurons exhibit dendritic spine loss, synaptic dysfunction, and eventual degeneration in response to Aβ and tau pathology.

“Neurons exhibit dendritic spine loss, synaptic dysfunction, and eventual degeneration in response to Aβ and tau pathology (Hoover et al., 2010; Shankar et al., 2007).”

• cites Hoover et al., 2010 sourceNot checked yet

  Not checked in the free run.

• cites Shankar et al., 2007 sourceNot checked yet

  Not checked in the free run.

May combine two claims.

Replenishing miR-29 or miR-107 restores APP/BACE1 repression and improves synaptic plasticity in experimental models.

“Replenishing miR-29 or miR-107 restores APP/BACE1 repression and improves synaptic plasticity in experimental models (Hébert et al., 2008; Kandel et al., 2021; Wang et al., 2008).”

• cites Hébert et al., 2008 sourceNot checked yet

  Not checked in the free run.

• cites Kandel et al., 2021Not matched

  Couldn’t be matched to a paper in Crossref, so it can’t be checked.

• cites Wang et al., 2008Not matched

  Couldn’t be matched to a paper in Crossref, so it can’t be checked.

May combine two claims.

miR-26b is upregulated in AD and activates CDK5/p25 signaling, promoting tau hyperphosphorylation, aberrant cell-cycle re-entry, and neuronal apoptosis.

“On the other hand, miR-26b is upregulated in AD and activates CDK5/p25 signaling, promoting tau hyperphosphorylation, aberrant cell-cycle re-entry, and neuronal apoptosis (Absalon et al., 2013).”

• cites Absalon et al., 2013 sourceNot checked yet

  Checked before — its earlier verdict is held back until a new check runs.

May combine two claims.

AD pathogenesis involves multiple CNS cell types-including neurons, astrocytes, microglia, oligodendrocytes, and, less prominently, neural stem cells, ependymal cells, and endothelial cells-which undergo coordinated but cell-type-specific pathological changes.

“AD pathogenesis involves multiple central nervous system (CNS) cell types—including neurons, astrocytes, microglia, and oligodendrocytes, and, less prominently, neural stem cells (NSCs), ependymal cells, and endothelial cells—which undergo coordinated but cell-type-specific pathological changes.”

May combine two claims.

Current biomarkers and therapies primarily focus on amyloid and tau pathology and do not fully capture the multicellular regulatory networks that drive disease progression.

“Despite these advances, current biomarkers and therapies primarily focus on amyloid and tau pathology and do not fully capture the multicellular regulatory networks that drive disease progression.”

May combine two claims.

MiR-206 is consistently elevated in AD cortex and serum, suppresses BDNF and IGF1, and is associated with synaptic decline and cognitive deficits.

“MiR-206 is consistently elevated in AD cortex and serum, suppresses BDNF and IGF1, and is associated with synaptic decline and cognitive deficits (Lee et al., 2012; Tian et al., 2014).”

• cites Lee et al., 2012 sourceNot checked — no full text of the source
• cites Tian et al., 2014 sourceNot checked yet

  Checked before — its earlier verdict is held back until a new check runs.

May combine two claims.

miR-140-5p disrupts PINK1-regulated mitophagy, and miR-199a-5p suppresses neuritin, limiting synaptic regeneration.

“Additionally, miR-140-5p disrupts PINK1-regulated mitophagy, and miR-199a-5p suppresses neuritin, limiting synaptic regeneration (Liang et al., 2021; Song et al., 2020).”

• cites Liang et al., 2021 sourceNot checked — no full text of the source
• cites Song et al., 2020 sourceNot checked yet

  Checked before — its earlier verdict is held back until a new check runs.

May combine two claims.

In AD, a subset of astrocytes undergoes reactive transformation, adopting inflammatory and metabolically altered states that compromise synaptic support and promote neurotoxicity.

“In AD, however, a subset of astrocytes undergoes reactive transformation, adopting inflammatory and metabolically altered states that compromise synaptic support and promote neurotoxicity (Heneka et al., 2015; Nassar et al., 2022).”

• cites Heneka et al., 2015 sourceNot checked yet

  Not checked in the free run.

• cites Nassar et al., 2022 sourceNot checked yet

  Checked before — its earlier verdict is held back until a new check runs.

May combine two claims.

The review provides a comprehensive cell-specific framework that maps how neuronal, astrocytic, microglial, oligodendrocytic, ependymal, endothelial, and neural stem cell miRNAs converge to shape AD pathology, outlining a multicellular regulatory network that has not been synthesized in prior literature.

“By providing a comprehensive cell-specific framework that maps how neuronal, astrocytic, microglial, oligodendrocytic, ependymal, endothelial, and neural stem cell miRNAs converge to shape AD pathology, we outline a multicellular regulatory network that has not been synthesized in prior literature.”

May combine two claims.

The miR-29 family targets both APP and BACE1, and its downregulation in AD cortex and hippocampus removes this brake, promoting amyloid formation.

“The miR-29 family (miR-29a/b-1/c) targets both proteins, and its downregulation in AD cortex and hippocampus removes this brake, promoting amyloid formation (Fan et al., 2020; Hébert et al., 2008).”

• cites Fan et al., 2020 sourceNot checked yet

  Checked before — its earlier verdict is held back until a new check runs.

• cites Hébert et al., 2008 sourceNot checked yet

  Not checked in the free run.

May combine two claims.

miR-219-5p suppresses tau kinases TTBK1 and GSK3β, and its loss in human AD entorhinal cortex destabilizes neuron-myelin coupling and promotes tau hyperphosphorylation.

“miR-219-5p, expressed in both neurons and oligodendrocytes, suppresses tau kinases TTBK1 and GSK3β, and its loss in human AD entorhinal cortex destabilizes neuron-myelin coupling and promotes tau hyperphosphorylation (Li et al., 2018).”

• cites Li et al., 2018Not matched

  Couldn’t be matched to a paper in Crossref, so it can’t be checked.

May combine two claims.

miR-338-5p targets BACE1 and the oligodendrocyte transcription factor SOX6.

“It targets BACE1 and the oligodendrocyte transcription factor SOX6, which has been linked to amyloid burden to impaired OL maturation (Qian et al., 2018).”

• cites Qian et al., 2018 sourceNot checked yet

  Not checked in the free run.

Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.

Adult hippocampal neurogenesis persists throughout life in rodents and in at least a subset of human studies.

“Adult hippocampal neurogenesis persists throughout life in rodents and in at least a subset of human studies, although its extent in aging and AD remains debated (Kempermann, 2015).”

• cites Kempermann, 2015 sourceNot checked yet

  Checked before — its earlier verdict is held back until a new check runs.

May combine two claims.

Restoring miR-219-5p enhances OL differentiation, preserves myelin integrity, and improves cognitive function.

“Restoring miR-219-5p enhances OL differentiation, preserves myelin integrity, and improves cognitive function (Dugas et al., 2010; Li et al., 2018).”

• cites Dugas et al., 2010 sourceNot checked yet

  Not checked in the free run.

• cites Li et al., 2018Not matched

  Couldn’t be matched to a paper in Crossref, so it can’t be checked.

May combine two claims.

MiR-155 is one of the strongest determinants of microglial pathogenicity; its upregulation in AD microglia enhances NF-κB signaling, increases production of pro-inflammatory cytokines, and reduces phagocytic Aβ clearance, thereby worsening plaque burden and neuronal injury.

“MiR-155 is one of the strongest determinants of microglial pathogenicity. Its upregulation in AD microglia enhances NF-κB signaling, increases production of pro-inflammatory cytokines, and reduces phagocytic Aβ clearance, thereby worsening plaque burden and neuronal injury (Cardoso et al., 2011; Guedes et al., 2014).”

• cites Cardoso et al., 2011 sourceNot checked — no full text of the source
• cites Guedes et al., 2014 sourceNot checked — no full text of the source

May combine two claims.

In a chronic cerebral hypoperfusion model, miR-9 upregulation increases BACE1 and suppresses CREB, contributing to cognitive impairment.

“In contrast, in a chronic cerebral hypoperfusion model that induces dementia-like pathology, miR-9 upregulation increases BACE1 and suppresses CREB, contributing to cognitive impairment and suggesting that, under vascular/metabolic stress, miR-9 may adopt maladaptive functions (Xie et al., 2017).”

• cites Xie et al., 2017 sourceNot checked — no full text of the source

May combine two claims.

miR-9 regulates NSC proliferation, differentiation, and neuronal integration, with context-dependent functional effects in AD-relevant contexts.

“Among these, miR-9 is one of the more extensively studied regulators of NSC proliferation, differentiation, and neuronal integration, and it displays context-dependent functional effects in AD-relevant contexts (Chang et al., 2014; Liu et al., 2020; Roese-Koerner et al., 2017; Xie et al., 2017).”

• cites Chang et al., 2014 sourceNot checked yet

  Checked before — its earlier verdict is held back until a new check runs.

• cites Liu et al., 2020 sourceNot checked — no full text of the source
• cites Roese-Koerner et al., 2017 sourceNot checked yet

  Checked before — its earlier verdict is held back until a new check runs.

May combine two claims.

Microglia play a dual and stage-dependent role in AD, initially contributing to Aβ clearance but transitioning into a chronically reactive, pro-inflammatory state under persistent pathological stress.

“Microglia, the brain's primary immune cells, play a dual and stage-dependent role in AD, initially contributing to Aβ clearance but transitioning into a chronically reactive, pro-inflammatory state under persistent pathological stress (Hansen et al., 2017; Heneka et al., 2015).”

• cites Hansen et al., 2017Not matched

  Couldn’t be matched to a paper in Crossref, so it can’t be checked.

• cites Heneka et al., 2015 sourceNot checked yet

  Not checked in the free run.

May combine two claims.

MiR-155 is induced in reactive astrocytes and is associated with pro-inflammatory glial reprogramming.

“MiR-155 is also induced in reactive astrocytes and is associated with pro-inflammatory glial reprogramming.”

• cites Aloi et al., 2023Not matched

  Couldn’t be matched to a paper in Crossref, so it can’t be checked.

• cites Cardoso et al., 2011 sourceNot checked — no full text of the source
• cites Guedes et al., 2014 sourceNot checked — no full text of the source

May combine two claims.

miR-338-5p is an oligodendroglial miRNA that is reduced in AD brains.

“miR-338-5p is another oligodendroglial miRNA reduced in AD brains.”

• cites Qian et al., 2018 sourceNot checked yet

  Not checked in the free run.

May combine two claims.

Disruptions in miRNA networks involving miR-219-5p, miR-338-5p, and miR-23a/b destabilize myelin maintenance, axonal metabolic support, and cytoskeletal integrity, contributing to early cognitive decline and impaired signal transmission in AD.

“The combined actions of miR-219-5p, miR-338-5p, and miR-23a/b highlight how disruptions in miRNA networks destabilize myelin maintenance, axonal metabolic support, and cytoskeletal integrity, contributing to early cognitive decline and impaired signal transmission in AD (Absalon et al., 2013; Dugas et al., 2010; Li et al., 2018; Lin et al., 2013; Qian et al., 2018).”

• cites Absalon et al., 2013 sourceNot checked yet

  Checked before — its earlier verdict is held back until a new check runs.

• cites Dugas et al., 2010 sourceNot checked yet

  Checked before — its earlier verdict is held back until a new check runs.

• cites Li et al., 2018Not matched

  Couldn’t be matched to a paper in Crossref, so it can’t be checked.

May combine two claims.

When miR-29a/b-1 is downregulated, repression of BACE1 and PUMA is lost, increasing amyloidogenic processing and compromising astrocyte survival.

“When miR-29a/b-1 is downregulated, repression of BACE1 and PUMA is lost, increasing amyloidogenic processing and compromising astrocyte survival (Hébert et al., 2008; Ouyang et al., 2013).”

• cites Hébert et al., 2008 sourceNot checked yet

  Not checked in the free run.

• cites Ouyang et al., 2013 sourceNot checked yet

  Not checked in the free run.

May combine two claims.

miR-23a/b is required for maintaining OPC and OL survival and nuclear integrity.

“Furthermore, miR-23a/b is required for maintaining OPC and OL survival and nuclear integrity.”

• cites Lin et al., 2013 sourceNot checked yet

  Not checked in the free run.

May combine two claims.

Disruption of the miR-34/449-CP110 axis could contribute to impaired ventricular cilia and CSF flow, though this has not yet been directly demonstrated in AD tissue.

“In combination with Aβ-induced ciliary slowing (Makibatake et al., 2023), this suggests that disruption of the miR-34/449-CP110 axis could contribute to impaired ventricular cilia and CSF flow, even though this has not yet been directly demonstrated in AD tissue (Song et al., 2014).”

• cites Makibatake et al., 2023 sourceNot checked yet

  Checked before — its earlier verdict is held back until a new check runs.

• cites Song et al., 2014 sourceNot checked yet

  Checked before — its earlier verdict is held back until a new check runs.

• AssumptionThe authors state this as an assumption: Direct ependymal-cell-specific miRNA profiling studies in AD brain tissue or AD animal models are currently lacking.

May combine two claims.

MiR-181c-5p is downregulated in AD microglia, and this loss weakens Aβ phagocytosis while amplifying p38-MAPK-dependent inflammatory signaling.

“MiR-181c-5p is downregulated in AD microglia, and this loss weakens Aβ phagocytosis while amplifying p38-MAPK–dependent inflammatory signaling (Li et al., 2024).”

• cites Li et al., 2024Not matched

  Couldn’t be matched to a paper in Crossref, so it can’t be checked.

May combine two claims.

MiR-34a is strongly induced in AD and directly represses TREM2 and SIRT1, both essential for microglial metabolic fitness, phagocytosis, and transition into the disease-associated microglial (DAM) state.

“MiR-34a is also strongly induced in AD and exerts multifaceted pathogenic effects. It directly represses TREM2 and SIRT1, both essential for microglial metabolic fitness, phagocytosis, and transition into the disease-associated microglial (DAM) state (Bhattacharjee et al., 2014; Sarkar et al., 2016; Sarkar et al., 2019).”

• cites Bhattacharjee et al., 2014 sourceNot checked yet

  Checked before — its earlier verdict is held back until a new check runs.

• cites Sarkar et al., 2016 sourceNot checked yet

  Checked before — its earlier verdict is held back until a new check runs.

• cites Sarkar et al., 2019 sourceNot checked yet

  Checked before — its earlier verdict is held back until a new check runs.

May combine two claims.

Because miR-219-5p is required for oligodendrocyte maturation and expression of major myelin proteins, its loss impairs myelin maintenance and axonal support while simultaneously promoting tau pathology through de-repression of these kinases.

“Because miR-219-5p is required for oligodendrocyte maturation and expression of major myelin proteins, its loss impairs myelin maintenance and axonal support while simultaneously promoting tau pathology through de-repression of these kinases (Dugas et al., 2010; Li et al., 2018).”

• cites Dugas et al., 2010 sourceNot checked yet

  Not checked in the free run.

• cites Li et al., 2018Not matched

  Couldn’t be matched to a paper in Crossref, so it can’t be checked.

May combine two claims.

miR-219-5p represses tau kinases TTBK1 and GSK3β, linking its downregulation in AD to both myelin dysfunction and tau hyperphosphorylation.

“Mechanistically, miR-219-5p represses tau kinases TTBK1 and GSK3β, linking its downregulation in AD to both myelin dysfunction and tau hyperphosphorylation (Li et al., 2018).”

• cites Li et al., 2018Not matched

  Couldn’t be matched to a paper in Crossref, so it can’t be checked.

May combine two claims.

Restoring miR-181c-5p in primary microglia improves Aβ uptake and suppresses pro-inflammatory cytokine release.

“Restoring miR-181c-5p in primary microglia improves Aβ uptake and suppresses pro-inflammatory cytokine release, indicating a protective role that is lost during disease progression (Li et al., 2024).”

• cites Li et al., 2024Not matched

  Couldn’t be matched to a paper in Crossref, so it can’t be checked.

May combine two claims.

BBB dysfunction is an early and independent contributor to AD pathogenesis, involving pericyte loss, tight-junction breakdown, and increased vascular permeability.

“BBB dysfunction is now recognized as an early and independent contributor to AD pathogenesis, involving pericyte loss, tight-junction breakdown, and increased vascular permeability (Montagne et al., 2017; Sweeney et al., 2018).”

• cites Montagne et al., 2017 sourceNot checked yet

  Not checked in the free run.

• cites Sweeney et al., 2018 sourceNot checked yet

  Not checked in the free run.

May combine two claims.

Genetic deletion of microglial miR-155 reduces Aβ pathology but produces network hyperexcitability and seizure susceptibility.

“Genetic deletion of microglial miR-155 reduces Aβ pathology but produces network hyperexcitability and seizure susceptibility, highlighting a critical trade-off between inflammation control and neuronal stability (Aloi et al., 2023).”

• cites Aloi et al., 2023Not matched

  Couldn’t be matched to a paper in Crossref, so it can’t be checked.

May combine two claims.

In AD-related contexts, miR-181a is downregulated in astrocytes, where it normally prevents excessive GFAP/S100B reactivity and supports balanced survival signaling.

“In AD-related contexts, miR-181a is downregulated in astrocytes, where it normally prevents excessive GFAP/S100B reactivity and supports balanced survival signaling (Hutchison et al., 2013; Stary et al., 2017).”

• cites Hutchison et al., 2013 sourceNot checked yet

  Checked before — its earlier verdict is held back until a new check runs.

• cites Stary et al., 2017 sourceNot checked yet

  Checked before — its earlier verdict is held back until a new check runs.

May combine two claims.

Hypoxia-responsive miR-210 is induced in metabolically stressed astrocytes, where it targets ISCU and components of the mitochondrial respiratory chain, shifting astrocytes toward glycolysis and weakening oxidative metabolic support for neurons.

“On the other hand, hypoxia-responsive miR-210 is induced in metabolically stressed astrocytes, where it targets ISCU and components of the mitochondrial respiratory chain, shifting astrocytes toward glycolysis and weakening oxidative metabolic support for neurons (Liang et al., 2021).”

• cites Liang et al., 2021 sourceNot checked — no full text of the source

May combine two claims.

Downregulation of miR-338-5p increases BACE1 expression, potentially accelerating Aβ accumulation, and blocks myelin gene induction.

“Downregulation of miR-338-5p increases BACE1 expression, potentially accelerating Aβ accumulation, while simultaneously blocking myelin gene induction, making miR-338-5p a rare dual-pathway regulator affecting both neuron-derived amyloid production and glial-derived myelin synthesis (Qian et al., 2018).”

• cites Qian et al., 2018 sourceNot checked yet

  Not checked in the free run.

May combine two claims.

Inhibition or deletion of miR-33 restores ABCA1/ApoE function, enhances Aβ phagocytosis, and reduces plaque burden.

“Inhibition or deletion of miR-33 restores ABCA1/ApoE function, enhances Aβ phagocytosis, and reduces plaque burden, directly linking miRNA dysregulation to AD lipid-genetic risk pathways (Tate et al., 2024).”

• cites Tate et al., 2024 sourceNot checked yet

  Not checked in the free run.

May combine two claims.

Experimental loss of miR-23a reduces myelin gene expression and increases OL susceptibility to stress.

“Experimental loss of miR-23a reduces myelin gene expression and increases OL susceptibility to stress (Lin et al., 2013).”

• cites Lin et al., 2013 sourceNot checked yet

  Not checked in the free run.

May combine two claims.

MiR-146a serves as a classical NF-κB-induced negative-feedback regulator; elevated miR-146a in microglia acts to inhibit IRAK1 and TRAF6.

“MiR-146a serves as a classical NF-κB–induced negative-feedback regulator. Elevated miR-146a in microglia acts to inhibit IRAK1 and TRAF6 (Fan et al., 2020; Lukiw et al., 2008; Saba et al., 2012; Saba et al., 2014).”

• cites Fan et al., 2020 sourceNot checked yet

  Checked before — its earlier verdict is held back until a new check runs.

• cites Lukiw et al., 2008 sourceNot checked yet

  Checked before — its earlier verdict is held back until a new check runs.

• cites Saba et al., 2012 sourceNot checked yet

  Not checked in the free run.

May combine two claims.

miR-21-5p is a multifunctional glial miRNA that participates in inflammatory signaling across multiple CNS cell types.

“Additionally, miR-21-5p represents another multifunctional glial miRNA that participates in inflammatory signaling across multiple CNS cell types.”

May combine two claims.

miR-155 is a glia-enriched miRNA; elevated miR-155 promotes pathogenic inflammatory signaling in microglia.

“MiR-155 exemplifies how a glia-enriched miRNA can influence multiple CNS cell types. As described in Section 2.3, elevated miR-155 promotes pathogenic inflammatory signaling in microglia.”

May combine two claims.

Inhibition of miR-155 using antagomirs reduces microglial inflammatory activation and improves pathological outcomes in experimental AD models.

“For example, inhibition of miR-155 using antagomirs has been shown to reduce microglial inflammatory activation and improve pathological outcomes in experimental AD models (Aloi et al., 2023; Guedes et al., 2014).”

• cites Aloi et al., 2023Not matched

  Couldn’t be matched to a paper in Crossref, so it can’t be checked.

• cites Guedes et al., 2014 sourceNot checked — no full text of the source

May combine two claims.

Loss of miR-132-3p contributes to neuronal dysfunction and AD pathology.

“As discussed in Section 2.1, loss of miR-132-3p contributes to neuronal dysfunction and AD pathology.”

May combine two claims.

Oligodendrocyte miRNAs, most prominently miR-219-5p and miR-338-5p, bridge myelin maintenance, OPC maturation, and tau-kinase or APP/BACE1 regulation, linking white-matter degeneration to classical AD pathology.

“Oligodendrocyte miRNAs, most prominently miR-219-5p and miR-338-5p, bridge myelin maintenance, OPC maturation, and tau-kinase or APP/BACE1 regulation, linking white-matter degeneration to classical AD pathology (Dugas et al., 2010; Li et al., 2018; Qian et al., 2018).”

• cites Dugas et al., 2010 sourceNot checked yet

  Not checked in the free run.

• cites Li et al., 2018Not matched

  Couldn’t be matched to a paper in Crossref, so it can’t be checked.

• cites Qian et al., 2018 sourceNot checked yet

  Not checked in the free run.

Probably not a substantial claim: may not pass S4 (based). May combine two claims.

Disease-associated factors such as Aβ, tau aggregates, cytokines, and metabolic stress may further reprogram the miRNA machinery in cell-specific ways, explaining why the same miRNA can be downregulated in one compartment but upregulated in another.

“Disease-associated factors such as Aβ, tau aggregates, cytokines, and metabolic stress may further reprogram this machinery in cell-specific ways, explaining why the same miRNA can be downregulated in one compartment but upregulated in another.”

May combine two claims.

Let-7b, elevated in CSF, acts as an endogenous TLR7 ligand, linking its fluid-level increase to direct neurotoxic signaling.

“Let-7b, elevated in CSF, acts as an endogenous TLR7 ligand, linking its fluid-level increase to direct neurotoxic signaling (Lehmann et al., 2012).”

• cites Lehmann et al., 2012 sourceNot checked — no full text of the source

May combine two claims.

AD progression is driven not only by cell-type-specific miRNA dysregulation but also by a shared network of multifunctional miRNAs whose effects span neuronal, glial, and vascular systems.

“Altogether, these findings show that AD progression is driven not only by cell-type-specific miRNA dysregulation but also by a shared network of multifunctional miRNAs whose effects span neuronal, glial, and vascular systems.”

May combine two claims.

miR-124-3p is a neuron-enriched miRNA that supports neuronal identity, synaptic stability, and AD-relevant stress responses.

“As described in Section 2.1, miR-124-3p is a neuron-enriched miRNA that supports neuronal identity, synaptic stability, and AD-relevant stress responses.”

Probably not a substantial claim: may not pass S3 (load-bearing), S4 (based).

miR-146a modulates inflammatory signaling through a conserved negative-feedback pathway.

“As described in Sections 2.2 and 2.3, its primary role is to modulate inflammatory signaling through a conserved negative-feedback pathway.”

May combine two claims.

Astrocytic and microglial miRNAs, including miR-21-5p, miR-155, miR-33, miR-146a, and miR-181c-5p, govern processes such as NF-κB-dependent inflammatory activation, ApoE/ABCA1 lipid pathways, and microglial plaque-associated phenotypes.

“Astrocytic and microglial miRNAs, including miR-21-5p, miR-155, miR-33, miR-146a, and miR-181c-5p, govern processes such as NF-κB–dependent inflammatory activation, ApoE/ABCA1 lipid pathways, and microglial plaque-associated phenotypes (Aloi et al., 2023; Cardoso et al., 2011; Fan et al., 2020; Garcia et al., 2022; Hansen et al., 2017; Hutchison et al., 2013; Li et al., 2024; Lukiw et al., 2008; O”

• cites Aloi et al., 2023Not matched

  Couldn’t be matched to a paper in Crossref, so it can’t be checked.

• cites Cardoso et al., 2011 sourceNot checked — no full text of the source
• cites Fan et al., 2020 sourceNot checked yet

  Checked before — its earlier verdict is held back until a new check runs.

May combine two claims.

miR-9-5p and miR-598 are depleted in whole CSF from AD patients but enriched in exosome-enriched CSF fractions.

“In one study, Riancho and colleagues demonstrated that miR-9-5p and miR-598 are depleted in whole CSF from AD patients but enriched in exosome-enriched CSF fractions, underscoring how EV trafficking and subfraction choice can profoundly influence biomarker readouts (Riancho et al., 2017).”

• cites Riancho et al., 2017 sourceNot checked — no full text of the source

Probably not a substantial claim: may not pass S2 (checkable), S4 (based).

AD is increasingly defined not by single pathogenic cascades, but by progressive disruption of miRNA-regulated communication across neural circuits.

“AD is increasingly defined not by single pathogenic cascades, but by progressive disruption of miRNA-regulated communication across neural circuits.”